Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Anyone presenting a clean league table of weight loss percentages is presenting something the evidence does not support
doi: 10.1056/NEJMoa2312323 Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al
30 The CAMELLIATIMI 61 trial (Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese PatientsThrombolysis in Myocardial Infarction 61) investigated the long-term cardiovascular safety and efficacy of lorcaserin in obese or overweight patients with cardiovascular disease or risk factors
Wang et al., 2014
References: Klausen et al., The Lancet 2026
US$ 20.14
US$ 25.56
.png)
US$ 20.77
US$ 29.47
US$ 25.36
US$ 27.54
US$ 26.57
